パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Teva Pharmaceutical Industries Limited 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。58

アナリスト	機関
Jasper Hellweg	Argus Research Company
Richard Silver	Barclays
Balaji Prasad	Barclays

Teva Pharmaceutical Industries 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Held Back By Insufficient Growth Even After Shares Climb 26%

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Generics And Biosimilars Pipeline And Expansion Will Define Progress

Carella, Byrne, Cecchi, Brody & Agnello, P.C. Announces New $2.25 Million Settlement of Class-Action Lawsuit Involving Persons and Entities that Purchased, Paid for, and/or Provided Reimbursement for Effexor XR and/or its Generic Equivalent

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 05, 2025

Teva Announces Fda Filing Acceptance for Ajovy®? (Fremanezumab) in Pediatric Episodic Migraine Prevention

Consensus EPS estimates increase by 74%

Teva Pharmaceutical Industries Limited to Report Q1, 2025 Results on May 07, 2025

Executive VP & CFO notifies of intention to sell stock

Sanofi Announces New Duvakitug Data Reinforce Best-In-Class Potential in Ulcerative Colitis and Crohn's Disease

Teva Pharmaceutical: A Risky Bet With Potential Upside

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Teva Pharmaceuticals and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Consensus EPS estimates fall from profit to US$0.056 loss

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept)

Insider notifies of intention to sell stock

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2025

Full year 2024 earnings: EPS misses analyst expectations

There's No Escaping Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Muted Revenues Despite A 27% Share Price Rise

Price target increased by 7.6% to US$24.06

Duvakitug And Teva's Growth: A Game Changer In Pharma

Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024

Cheap Teva Stock Should Reward Patient Investors

Insider notifies of intention to sell stock

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024

Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024

Price target increased by 8.5% to US$16.44

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

A Review Of Teva's Prospects

Price target increased by 11% to US$13.75

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

Price target increased by 7.8% to US$12.59

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity

Teva: Deeply Undervalued FCF Machine

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023

Teva Announces Changes to Executive Management Team

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

配当金基準チェック /06